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Adoptive transfer of high avidity tumor-specific CD8 T
cells is a promising treatment for late stage cancers.
Because most tumor antigens are self-antigens, tumor-
specific T cells typically express low affinity T cell anti-
gen receptors (TCR) due to thymic negative selection,
which accounts mostly for their poor tumoricidal activ-
ity. To identify rare, most tumor-reactive T cells we
developed a robust and accurate screening assay. The
functional avidity of T cell responses is related to
pMHC-TCR binding parameters, with an assumed opti-
mal range of pMHC-TCR affinity for the most potent
interaction. We recently described the development of
NTAmers[1], reversible pMHC multimers built on
switchable Ni2+-NTA-His-tag complexes, that allow
accurate measurement of monomeric pMHC-TCR dis-
sociation kinetics on living tumor-specific CD8 T cells
by flow cytometry. We found a good correlation
between off-rates and cellular responses on cloned CD8
T cells from cancer patients[2]. Moreover we developed
pMHC dimers allowing measurement of pMHC-TCR
association and dissociation kinetics on cancer-specific
T cells. Combined measurement of pMHC-TCR on and
off rates allowed accurate identification and isolation of
functional high avidity tumor-specific CD8 T cells. In
vivo experiments confirmed that high avidity CD8 T
cells isolated from a cancer patient conferred superior
tumor control. This novel technology has further
allowed us to describe the functional involvement of the
CD8 co-receptor in this interaction. Using CD8-binding
deficient pMHC complexes, we observed that CD8
increases on CD8 T cells the off-rate by 3-4 fold but has
no discernable effect on the on-rate.
In conclusion, NTAmers and pMHC dimers enable
precise measurement of pMHC-TCR binding para-
meters under physiological conditions and subsequent
isolation of live functionally active tumor-specific CD8
T cells. Translation of these techniques to the single cell
level for high-throughput screening and isolation of rare
and highly functional tumor-specific CD8 T cells
directly from cancer patients is in progress.
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